Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Uma Borate, Amy S. Ruppert, Fei Yang, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Amy Burd, Dean Pavlick, Luke Juckett, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Gary J. Schiller, William Blum, Tibor Kovacsovics, Mark Litzow, James M. Foran, Nyla A. Heerema, Leonard Rosenberg, Sonja Marcus, Ashley Owen Yocum, Mona Stefanos, Brian J. Druker, John C. Byrd, Ross L. Levine, Alice S. Mims
Institutions: Oregon Health & Science University, OHSU Knight Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Foundation Medicine (United States), Blood Cancer United, Memorial Sloan Kettering Cancer Center, The University of Texas Southwestern Medical Center, University of Maryland, Baltimore, University of Chicago, University of California, Los Angeles, Winship Cancer Institute, University of Utah, Mayo Clinic, Mayo Clinic in Florida, University of California San Diego
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2986794129